Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.

PURPOSE: We have shown previously that tumor infiltration by FOXP3+ regulatory T cells (Treg) is associated with increased relapse and shorter survival of patients with both in situ and invasive breast cancer. Because estrogen regulates Treg numbers in mice and promotes the proliferation of human T...

Podrobná bibliografie
Hlavní autoři:	Generali, D, Bates, G, Berruti, A, Brizzi, M, Campo, L, Bonardi, S, Bersiga, A, Allevi, G, Milani, M, Aguggini, S, Dogliotti, L, Banham, A, Harris, A, Bottini, A, Fox, S
Médium:	Journal article
Jazyk:	English
Vydáno:	2009

Podobné jednotky

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Autor: Generali, D, a další
Vydáno: (2008)

Effect of primary letrozole (LET) vs letrozole plus metronomic cyclophosphamide (LET-CYC) on Treg infiltration in ER plus ve breast cancer.
Autor: Fox, S, a další
Vydáno: (2006)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
Autor: Fox, S, a další
Vydáno: (2011)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
Autor: Fox, S, a další
Vydáno: (2011)

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
Autor: Mele, T, a další
Vydáno: (2010)

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients
Autor: Mele, T, a další
Vydáno: (2010)

Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
Autor: Generali, D, a další
Vydáno: (2009)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer
Autor: Generali, D, a další
Vydáno: (2007)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer.
Autor: Generali, D, a další
Vydáno: (2007)

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
Autor: Generali, D, a další
Vydáno: (2006)

Principal factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients.
Autor: Generali, D, a další
Vydáno: (2006)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
Autor: Allevi, G, a další
Vydáno: (2013)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
Autor: Allevi, G, a další
Vydáno: (2013)

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
Autor: Generali, D, a další
Vydáno: (2006)

DOWN-REGULATION OF HYPOXIA INDUCIBILE FACTOR-1 alpha (HIF-1 alpha) EXPRESSION, THROUGH mTOR PATHWAY, BY LETROZOLE (FEMARA (R)) IN ER plus ve BREAST CANCER PATIENTS: CLINICAL IMPLICATIONS
Autor: Foroni, C, a další
Vydáno: (2009)

Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
Autor: Generali, D, a další
Vydáno: (2011)

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
Autor: Generali, D, a další
Vydáno: (2008)

ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment
Autor: A Ianza, a další
Vydáno: (2020-06-01)

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer
Autor: Andreis, D, a další
Vydáno: (2016)

Effect of Letrozole Administration as a Selective Aromatase Inhibitor on Male Rat's Reproductive Performance
Autor: A Hmood Jassim, a další
Vydáno: (2022-02-01)

Synergistic activity of letrozole and sorafenib on breast cancer cells.
Autor: Bonelli, M, a další
Vydáno: (2010)

Estrogen/androgen balance in men with hyperestrogenism normalized by using letrozole of the aromatase inhibitor drug class
Autor: Z. Sh. Pavlova, a další
Vydáno: (2022-03-01)

Interaction of Zinc Chloride with an Aromatase Inhibitor (Letrozole) on Anxiety in Adult Male Rats
Autor: Sahar Charghan, a další
Vydáno: (2016-12-01)

#120 : Effect of Aromatase Inhibitor, Letrozole on Semen Parameters in Eugonadotropic Hypoandrogenic Men with Oligozoospermia
Autor: Israt Jahan
Vydáno: (2023-12-01)

Effect of Aromatase Inhibitor Letrozole on the Placenta of Adult Albino Rats: A Histopathological, Immunohistochemical, and Biochemical Study
Autor: Mohamed Ali Alabiad, a další
Vydáno: (2024-01-01)

Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas.
Autor: Bates, G, a další
Vydáno: (2008)

Letrozole, an aromatase inhibitor, improves seminal parameters and hormonal profile in aged endangered Markhoz bucks
Autor: Ako Rezaei, a další
Vydáno: (2022-11-01)

The aromatase inhibitor letrozole enhances the effect of doxorubicin and docetaxel in an MCF7 cell line model
Autor: Mary O’Neill, a další
Vydáno: (2012-12-01)

Therapeutic targeting of FOXP3-positive regulatory T cells using a FOXP3 peptide vaccine WO2008081581.
Autor: Banham, A, a další
Vydáno: (2009)

Design of Novel Letrozole Analogues Targeting Aromatase for Breast Cancer: Molecular Docking, Molecular Dynamics, and Theoretical Studies on Gold Nanoparticles
Autor: Alaa Edris, a další
Vydáno: (2023-04-01)

The FOXP3 transcription factor as a regulatory T-cell marker
Autor: Banham, A
Vydáno: (2008)

Interaction of letrozole and its degradation products with aromatase: chemometric assessment of kinetics and structure-based binding validation
Autor: Michele De Luca, a další
Vydáno: (2022-12-01)

Effectiveness of the aromatase (P450 Arom) inhibitors Letrozole and Exemestane for masculinization of red tilapia (Oreochromis spp.)
Autor: John J Betancur López, a další
Vydáno: (2014-03-01)

High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma.
Autor: Carreras, J, a další
Vydáno: (2006)

Monoclonal antibodies raised to the human FOXP3 protein can be used effectively for detecting Foxp3(+) T cells in other mammalian species.
Autor: Banham, A, a další
Vydáno: (2009)

The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer.
Autor: Giatromanolaki, A, a další
Vydáno: (2008)

Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers.
Autor: Rayoo, M, a další
Vydáno: (2009)

FOXP3+ regulatory T cells as biomarkers in human malignancies.
Autor: Bignone, P, a další
Vydáno: (2008)

Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer
Autor: Panagiotis A. Konstantinopoulos, a další
Vydáno: (2024-04-01)

FOXP1: a potential therapeutic target in cancer.
Autor: Koon, H, a další
Vydáno: (2007)